cyrilzakka/clinical-trials huggingface dataset:
Retrospective Epidemiological Study of Lung Cancer With Low-dose Multislice Computed Tomography

Lung cancer is one of the leading causes of cancer-related death in Taiwan. Early diagnosis of lung cancer may improve cancer survival. Low-dose computed tomography (LDCT) was thought to be the best screening tool for lung cancer. However, there is growing concerns about radiation exposure, high cost, and high rate of false-positive screening result. Epidemiology data for LDCT screening in Taiwan is lacking.

National Taiwan University Hospital Chu-Tung Branch (NTUHCT) initiated the lung cancer screening by LDCT since June 2015. Many people can get the LDCT screening with affordable price with the subsidy from enterprise donation. The purpose of this study is establishing local epidemiological result via telephone follow-up and patients' medical records retrospectively.

Lung cancer is one of the leading causes of cancer-related death in Taiwan. Early diagnosis of lung cancer may improve cancer survival. Low-dose computed tomography (LDCT) was thought to be the best screening tool for lung cancer. However, there is growing concerns about radiation exposure, high cost, and high rate of false-positive screening result. Epidemiology data for LDCT screening in Taiwan is lacking.

National Taiwan University Hospital Chu-Tung Branch (NTUHCT) initiated the lung cancer screening by LDCT since June 2015. Many people can get the LDCT screening with affordable price with the subsidy from enterprise donation. The purpose of this study is establishing local epidemiological result via telephone follow-up and patients' medical records retrospectively.

Aim: To establish the local epidemiological data for lung pathology, emphysema, bronchiectasis and other lung disease.

Methods: Since June 2015, more than 6000 LDCT were done at the NTUHCT. Roughly 6 months after the test telephone follow-ups about patient satisfactions, self-awareness of CT results, medical consultations and other related behaviors, and willingness of coming back for another test were routinely done. Retrospective secondary data analysis will be performed on the telephone follow-up results to establish local epidemiology data on lung pathology as well as information on screening accuracy of LDCT. Customers are also queried about willingness to provide their medical records, and linkage to National Health Insurance Database with informed consents to provide more advanced information on their long-term outcomes.

Keywords: Lung cancer, Low dose computed tomography, screening.

Eligibility Criteria:
Inclusion Criteria:

* self pay the LDCT in National Taiwan University Hospital Chu-Tung Branch

Exclusion Criteria:

-
Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer

Introduction. Cisplatin-induced ototoxicity is a very frequent event and its consequences can cause a lot of deterioration in patients. Early diagnosis is essential because it would allow the appropriate implementation of strategies to reduce its effect. Among these N-acetylcysteine, an antioxidant agent that has shown otoprotective effect. Study design. Randomized, parallel design and placebo controlled clinical trial. Methods. Patients with head and neck cancer who require treatment with cisplatin were enrolled in 2 branches: a control group that receives a placebo and experimental group that receives the drug. High-frequency audiometries (6 - 16 KHz) are performed before, during and after the treatment finalization.


Eligibility Criteria:
Inclusion Criteria:

* Adults Patients with Head and Neck Squamous Cell carcinoma requiring Chemoradiotherapy including Cisplatin.

Exclusion Criteria:

* Conductive Hearing Loss
* SNHL with \>= 40db PTA
Patient-derived Stem Cell Models of Anorexia Nervosa

Experimental and genetic data, as well as brain imaging, support a role of the hypothalamic Arcuate nucleus neurons and their communication with surrounding microglia in anorectic conditions, but it has until recently not been possible to explore these cells at a molecular level in anorexia nervosa (AN) patients. This attributed to the obvious lack of valid tissue and non-invasive imaging techniques of high enough resolution. Stem cell models have evolved as a useful tool for the exploration of other neuropsychiatric disorders with a comparably high genetic contribution as AN. The investigators will here use patient-derived induced pluripotent stem cells (iPSCs) to profile Arc neurons and peripheral blood mononuclear cell (PBMC) derived microglia in AN, thus defining molecules to explore as drug targets.


Eligibility Criteria:
Inclusion Criteria anorexia nervosa:

* female
* 18-45 years of age
* AN restrictive diagnosis as main diagnosis
* more than 5 years duration

Exclusion Criteria anorexia nervosa:

-

Inclusion Criteria healthy control:

* female
* 18-45 years of age
* BMI 18,5 - 25

Exclusion Criteria healthy control:

* own or family member with eating disorder diagnosis
* own or family member with autism diagnosis
Pain Control in Hip Arthroscopy: Comparing Lumbar Plexus Versus Peri-capsular Injection

Comparison of lumbar plexus nerve block versus pericapsular injection for pain control during hip arthroscopy

The purpose of this study is to compare two different methods of pain control during and after hip arthroscopy surgery. It is not clear which of many different pain control methods are ideal to reduce pain for patients; consequently, the investigators are performing this study to compare the two main choices for pain control commonly used in order to identify if either is superior to the other.

Eligibility Criteria:
Inclusion Criteria:

1. Patient scheduled to undergo hip arthroscopy with Dr. Wolff
2. Patient age between 25 and 60 years of age.

Exclusion Criteria:

1. Patient has known allergy to ropivicaine or morphine.
2. Patient unable to speak/read English (No translators available in clinic site).
3. Pregnant female.
4. Patient has a pre-operative narcotic use for hip pain
5. Patient has pre-existing chronic pain disorder (i.e. fibromyalgia)
Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)

Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and August 31, 2009 must be consecutively screened and, if eligible, enrolled. Patients will be followed up at maximum until August 31, 2011. Switch to any other Anti vascUlar endothelial growth factor (anti VEGF) treatment will be documented and followed up. For each patient, demographics, medical history, administered treatments, results of ocular and visual assessments and other tests (where available) will be documented.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of wet age-related macular degeneration
* Start of Anti vascUlar endothelial growth factor (anti VEGF) therapy with ranibizumab between January 1, 2009 and August 31, 2009
* Informed consent form signed, where required

Exclusion Criteria:

* Participation in an investigational study during anti-VEGF therapy (from start up to August 31, 2011) that involved treatment with any drug or medical device
Influence of Facebook Ads on Food Choice

This is a randomized trial to examine the influence of race-congruent food marketing on social media among Black and White adolescents.

The overall objective of our three studies is to identify the extent to which exposure to Facebook food ads increases the number of calories purchased and consumed by Black and White adolescents. Guided by strong preliminary data, the study team will test three aims: 1)To evaluate the extent to which exposure to racially congruent vs. incongruent Facebook food ads causes Black vs. White adolescents to purchase more calories for a snack; 2)To determine the extent to which exposure to many vs. few "likes" on Facebook food ads causes Black and White adolescents to purchase more calories for a snack; and 3)To test the degree to which visual attention to unhealthy foods, racially congruent people, and/or "likes" in Facebook ads explains the relationship between ad exposure and calorie intake.

Eligibility Criteria:
Inclusion Criteria:

* adolescent (13-17 years of age)
* who identifies as only non-Latino White or only Black/African American
* who logs into Facebook once daily
* who can read and speak English

Exclusion Criteria:

* participants who do not meet all criteria described above.
The Optimal Sequence in Same-day Bidirectional Endoscopy Under Deep Anesthesia.

The purpose of this study is to explore the optimal sequence of same-day bidirectional endoscopy under deep anesthesia induced by propofol combined with fentanyl.

Same-day bidirectional endoscopy are commonly performed to evaluate iron deficiency anemia, positive fecal occult blood, abdominal pain and cancer screening. In order to reducing intraoperative pain, providing better operating conditions and improving the endoscopic examination quality, endoscopy with anesthesia assistance has gradually become the choice of more patients. However, the optimal sequence of procedures for same-day bidirectional endoscopy has not been established. This is a two-center, single-blind, randomized, controlled trial. Patients undergoing same-day bidirectional endoscopy under deep sedation will be randomly assigned to either the colonoscopy-first group (colonoscopy followed by EGD, n = 272) or the EGD(esophagogastroduodenoscopy)-first group (EGD followed by colonoscopy, n = 272).The detection rate of adenoma（ADR）, the ADR of right-side colon , Boston score of right-side colon, total dose of anesthetics, operation time, recovery time, adverse events and patient satisfaction will be evaluated.

Eligibility Criteria:
Inclusion Criteria:

* Any patient with a clinical indication for receiving same day bi-directional endoscopies.

Exclusion Criteria:

* Contraindications of colonoscopy: acute peritonitis; intestinal perforation or suspected intestinal perforation; acute anorectal infection or painful lesions; menstruation; pregnancy; cardiopulmonary insufficiency; prior abdominal and pelvic surgery.
* Contraindications for EGD: severe heart disease, severe heart failure; severe lung disease: asthma : severe hypertension; acute perforation of esophagus, stomach and duodenum; acute severe pharynx and larynx disease gastroscopy can not be inserted; acute stage of corrosive esophageal injury; prior upper digestive tract operation.
* Contraindications for oral intestinal laxative: severe gastrointestinal obstruction or stricture; toxic megacolon; severe acute intestinal infection; dysphagia; disturbance of consciousness; allergy to drug ingredients.
* Allergic to emulsions or opioids.
* ASA score ≥ III
Hemopatch Compared to TachoSil in Postoperative Air Leak Duration After Pulmonary Resection

This study is a randomized, controlled study, with the primary objective to demonstrate non-inferiority of Hemopatch compared to TachoSil in postoperative air leak duration after pulmonary resection, and with the secondary objective of evaluating the safety of Hemopatch compared to TachoSil.


Eligibility Criteria:
Inclusion Criteria:

Preoperative-

* Patients, 18 years or older at the time of signing the informed consent form (ICF), undergoing elective pulmonary resections (lobectomy, segmentectomy, or wedge resection), either through open thoracotomy or through Visually Assisted Thoracotomy surgery (VATS)
* Patients or legally authorized representatives, who are able to give IC after an explanation of the proposed study, and who are willing to comply with the study requirements for therapy during the entire study treatment period
* If female of child-bearing potential, patient will present with a negative blood/urine pregnancy test, and will agree to employ adequate birth control measures for the duration of the study

Intraoperative-

* Patients with grade 1 or 2 (Macchiarini scale) air leakage after primary stapling and limited suturing

Exclusion Criteria:

Preoperative-

* Patients who had previous lung surgery (on the same side)
* Patients with an active, florid infection
* Patients who have received chemotherapy within the previous 3 weeks.
* Patients who have received radiation therapy within the previous 4 weeks.
* Patients with known hypersensitivity to the components of the investigational product and control (human fibrinogen, human thrombin, collagen of any origin, NHS-PEG)
* Patients undergoing emergency surgery
* Female patients of childbearing potential with a positive pregnancy test or intent to become pregnant during the clinical study period
* Female patients who are nursing
* Patients with exposure to another investigational drug or device clinical trial within 30 days prior to enrollment or anticipated in the 30 day study period till the End of study visit.
* Patient has a clinically significant concurrent medical condition (e.g. concomitant illness, drug/alcohol abuse) that, in the opinion of the investigator, could adversely affect patient's safety and/or compliance with study procedures
* Patient is a family member or employee of the investigator

Intraoperative-

* Patients with serious complications during surgery, including the need for adhesiolysis, and pneumonectomy.
* Patients who were treated with any surgical sealant
* Major intraoperative complications that require resuscitation or deviation from the planned surgical procedure
* Patients with any other intraoperative findings identified by the surgeon that may preclude the conduct of the study procedure
Laparoscopic Sleeve Gastrectomy: a Cohort Study

This is a prospective cohort study, which subjects were obese patients requiring LSG surgery. LSG with different gastric resection starting points (2-4cm/4-6 cm from pylorus) as intervention method. The main observation is the incidence and extent of upper gastrointestinal symptoms (such as nausea, vomiting, retching, reflux, difficulty swallowing, etc.).In addition, secondary observations include the excess weight loss (%EWL) and postoperative complications. Aim to investigate the effects of LSG surgery in different starting points of gastric resection on postoperative upper gastrointestinal symptoms.


Eligibility Criteria:
Inclusion Criteria:

* Patients were accepted for surgery if they satisfied the guidelines of the Society of Chinese Gastroenterological Surgeons \[body mass index (BMI) ≥40 kg/m2 or BMI ≥35 kg/m2 with at least one co-morbidity associated with obesity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea), age between 18 and 60 years, and failure of conservative treatment over 2 years\].
* All patients undergo preoperative upper gastrointestinal (GI) endoscopy.

Exclusion Criteria:

* any patient who had previously been submitted to any type of bariatric surgery;
* patient currently taking anti-nausea or GERD medications preoperatively;
* any current smokers；
* active duodenal/gastric ulcer disease；
* difficult to treat gastroesophageal reflux disease (GERD) with a large hiatal hernia；
* previous major gastrointestinal surgery；
* diagnosed or suspected malignancy；
* poorly controlled significant medical or psychiatric disorders；
* disorders such as a medical history of major pathology;
* can not be able to understand and willing to participate in this registry with signature.
Low-carbohydrate Versus Low-fat Breakfast in Type 2 Diabetes

The prevalence of type 2 diabetes (T2D) is increasing worldwide, with \~380 M currently suffering from this chronic, debilitating disease. T2D is characterized by high blood glucose levels in the mornings and after meals. The largest hyperglycemic spike often occurs after breakfast. Targeting this meal may be a simple, feasible strategy to improve glycemic control and reduce risk for diabetes complications. It is hypothesized that consuming a low carbohydrate high fat (LCHF) breakfast for 3 months, when compared to a standard low-fat breakfast will improve blood glucose control, increase satiety and improve body composition in people with T2D. This information will test whether the simple dietary strategy of limiting carbohydrates at breakfast could help in managing T2D.

A 3-month parallel-group randomized controlled trial will be conducted. Eligible participants will be randomized to either the Low-carb High-fat breakfast (LCHF, n=41) or a low-fat "standard care" control breakfast (CTL, n=41), to be consumed daily for a period of 3 months.

Due to COVID-19 pandemic, this study was adapted to be conducted remotely through video/telephone conference meetings between participants and study staff, along with mailing of study materials before and after the intervention for remote data collection.

Each group will be provided with a menu of 8 LCHF breakfasts or 8 CTL breakfasts from which to choose each morning. Breakfast options (designed by a registered dietitian) will be controlled in macronutrient content and calories (\~400-500 kcal), but allow for personal preference and autonomy to promote adherence.

Eligibility Criteria:
Inclusion Criteria:

* physician-diagnosed T2D of ≥1 year;
* current HbA1c of \< 8.5%;
* BMI: \>25 kg/m2; (as of July 5, 2021, BMI cut off was expanded from 25-40 kg/m2 to higher than 25kg/m2 to facilitate recruitment)
* blood pressure of \<160/99 mm Hg assessed according to guidelines;
* non-smoking;
* not on hormone replacement therapy, corticosteroids, or anti-inflammatory medications;
* 20-79 years old.

Exclusion Criteria:

* Use of exogenous insulin;
* taking more than 2 glucose lowering medications;
* ongoing medical treatment for diseases such as cancer, auto-immune or inflammatory disease, liver or kidney disorders;
* allergy, intolerance or aversion to eggs or any other dietary restrictions (e.g., vegan, breakfast skipping) that will prevent them from following the standardized study diets;
* being unable to follow remote guidance by internet or smartphone
* being unable to follow the controlled diet instructions;.
Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors

Study to assess the potential effects of lurbinectedin (PM01183) at a therapeutic dose on the duration of the QTc interval, measured by electrocardiograms (ECGs), to characterize the PM01183 plasma concentration/QTc relationship, and to explore related ECG parameters in patients with selected solid tumors.


Eligibility Criteria:
Inclusion Criteria:

* Voluntarily signed and dated informed consent
* Normal cardiac conduction and function (centrally read)
* Blood pressure between 90 and 150 mmHg systolic, inclusive, and not higher than 90 mmHg diastolic.
* Specific serum electrolyte levels

Exclusion Criteria:

* Age \> 65 years
* Performance status = 2 \[Eastern Cooperative Oncology Group (ECOG)\]
* Heart rhythm disturbances
* Significant ischemic coronary disease, heart failure, myocardial infarction, or unstable angina within the last six months.
* Prior exposure to anthracyclines at a cumulative dose of doxorubicin (or equivalent) \> 450 mg/m²
Identifying Changes in Food Behaviors Associated with Beginning GLP-1 Medication

In recent years, GLP-1 medications have become a widely employed approach by physicians to address weight concerns in patients and lead to weight loss. Little is known, however, about how these medications may alter an individual's attitude towards food, food reactivity, or the specific types and amounts of foods an individual will choose. The purpose of this study is to observe the changes an individual experiences in their relationship and reaction to food and in their food selection from prior to taking GLP-1 medication to after three months on the medication. The researchers of this study believe that an understanding of such changes can inform questions seeking to ensure maintenance of appropriate nutrient balance within individuals on weight loss medications.


Eligibility Criteria:
Inclusion Criteria:

* Adults (18+) with overweight or obesity (BMI \>25 kg/m2)
* Not currently taking an incretin-based medication at baseline
* Recently prescribed a GLP-1, can be included if they have a obesity-related co-occurring condition (diabetes, hypertension, cardiovascular disease, dyslipidemia)
* Have had no prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
* Fluent in English

Exclusion Criteria:

* Adults (18+) without overweight or obesity
* \<18 years of age at time of testing
* Adults not taking a GLP-1 Medication
* Adults taking a compound GLP-1
* Have had a prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
* Not fluent in English
Cyclosporine (CSA) Level in Blood Samples Collected From Different Lines

The purpose of this study is to verify whether differences exist in cyclosporine levels between the samples collected through peripheral venous access, the catheter line used to infuse the drug and the line not used for infusion immediately after interrupting the drug infusion or five minutes after the interruption.

Cyclosporine is an immunosuppressant that prevents graft-versus-host disease, has a narrow therapeutic window, and causes nephrotoxicity. For cyclosporine infusion, a tunneled central venous access device is used; however due to the lipophilic properties of the drug, it can adsorb to the catheter surface and falsely raise cyclosporine concentrations in blood specimens. Some authors recommend sample collection through peripheral access only. Others, however, have shown that these can be collected through the catheter line not used to infuse the drug. Controversies still exist, though, regarding the best timing and blood volume to be discarded to collect the sample.

The hypothesis adopted was that drug adsorption occurs in the line used for infusion. Therefore, there is no statistical or clinical difference between the blood sample collected from the peripheral venous access and from the line not used for cyclosporine infusion. Additionally, this difference becomes smaller when waits five minutes between the interruption of the infusion of the drug and the collection of the blood sample.

Eligibility Criteria:
Inclusion Criteria:

* Patients older than 18 years of age who are receiving an allogeneic hematopoietic stem cell transplantation;
* Have a tunneled central venous access device with at least two lines implanted;
* Received cyclosporine administration through this device.

Exclusion Criteria:

* Patients who received cyclosporine infusion through a catheter line other than the one established for this goal.
CT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection

In this project, the preoperative anatomical location of micro hepatocellular carcinoma under the guidance of CT can provide guidance for accurate surgical resection. It may also shorten the operation time and reduce intraoperative bleeding.

General and basic information of the patients included in the study was collected. After preoperative preparation was completed, on the day of surgery, disposable pulmonary nodular localization needle (Ningbo Sonjiecang Biological Technology Co., LTD., Model: SS510-10) was used for the localization of micro hepatocellular carcinoma that could be found by preoperative CT enhancement or MRI. After the micro hepatocellular carcinoma was located under the guidance of CT, and then the patient was sent to the operating room. During the operation, the lesion was removed according to the tail line of the positioning needle and the position of the positioning needle.

Eligibility Criteria:
Inclusion Criteria:

1. Be at least 18 years old and give informed consent to participate in the study
2. A preoperative (clinical, radiological, or histological) diagnosis of cirrhosis of the liver due to any cause.
3. micro hepatocellular carcinoma (diameter less than 1cm).
4. Preoperative CT plain scan could not find the lesion, and preoperative B-ultrasound could not find the lesion.
5. Preoperative CT enhancement or MRI can detect the lesion.

Exclusion Criteria:

1. Child-Pugh grade C
2. Uncontrolled Hypertension
3. Severe lung dysfunction
4. Severe cardiac dysfunction